Gold-based drug slows cancer tumor growth by 82%, outperforms chemotherapy
SMRTR summary
A novel gold-based drug demonstrates significant promise in combating cancer, reducing tumor growth by 82% in animal tests. It's 27 times more effective against cervical cancer cells than cisplatin, a standard chemotherapy drug, and surpasses it in treating prostate cancer and fibrosarcoma. The compound targets a specific enzyme prevalent in cancer cells, minimizing toxic side effects. It also inhibits blood vessel formation crucial for tumor growth, proving effective against various cancers, including drug-resistant ovarian cancer.
SMRTR provides this summary for quick context. The original article belongs to Interesting Engineering.
Read the original article